1,024
Registered trials
402
Recruiting
550
Completed trials
265
Sponsors active
171
Research sites
Phase III:
654
Phase II/III:
47
Phase II:
221
Phase I/II:
36
Phase III/IV:
8
Phase IV:
19
Phase I:
7
Phase I (Other):
20
Phase I (FiH):
8
Other:
3
Other:
1
Oversight events in trials active here:
37 serious breaches
380 temporary halts
18 urgent safety measures
29 unexpected events
59 corrective measures
across 152 trials
View oversight register →
Top conditions
Non-small cell lung cancer
48
Non-small cell lung cancer metastatic
17
Systemic lupus erythematosus
13
Pulmonary arterial hypertension
11
Chronic obstructive pulmonary disease
11
Colitis ulcerative
11
Small cell lung cancer extensive stage
10
Asthma
10
Idiopathic pulmonary fibrosis
9
Chronic kidney disease
8
Dementia Alzheimer's type
8
Myelofibrosis
7
Top sponsors
Merck Sharp & Dohme LLC
71
Sanofi-Aventis Recherche & Developpement
50
Amgen Inc.
41
AbbVie Deutschland GmbH & Co. KG
40
Novartis Pharma AG
40
AstraZeneca AB
37
Glaxosmithkline Research & Development Limited
34
Janssen - Cilag International
33
F. Hoffmann-La Roche AG
31
Bristol-Myers Squibb Services Unlimited Company
29
Eli Lilly & Co.
28
Pfizer Inc.
27
Cities with most trials
All 62 cities →All trials — page 19
1,024 total-
Asciminib Roll-over Study Recruiting
-
Pan tumor Roll Over Study Recruiting
Showing 433–456 of 1,024 trials